Romero-Carmona C, Chavez-Corona J, Lima E, Cortes H, Quintanar-Guerrero D, Bernad-Bernad M
J Nanobiotechnology. 2024; 22(1):802.
PMID: 39734205
PMC: 11682652.
DOI: 10.1186/s12951-024-03045-8.
Paul S, Bhuyan S, Balasoupramanien D, Palaniappan A
ACS Omega. 2024; 9(23):24121-24141.
PMID: 38882129
PMC: 11170654.
DOI: 10.1021/acsomega.3c10305.
Pratiwi R, El Muttaqien S, Gustini N, Difa N, Syahputra G, Rosyidah A
ADMET DMPK. 2023; 11(4):435-455.
PMID: 37937250
PMC: 10626508.
DOI: 10.5599/admet.1999.
Pessoa B, Collado-Gonzalez M, Sandri G, Ribeiro A
Mar Drugs. 2023; 21(3).
PMID: 36976228
PMC: 10057083.
DOI: 10.3390/md21030179.
Debele T, Park Y
Life (Basel). 2022; 12(12).
PMID: 36556443
PMC: 9783843.
DOI: 10.3390/life12122078.
Nanocarriers as a Delivery Platform for Anticancer Treatment: Biological Limits and Perspectives in B-Cell Malignancies.
Bozzer S, Dal Bo M, Grimaldi M, Toffoli G, Macor P
Pharmaceutics. 2022; 14(9).
PMID: 36145713
PMC: 9502742.
DOI: 10.3390/pharmaceutics14091965.
Natural Polysaccharide-Based Nanodrug Delivery Systems for Treatment of Diabetes.
Qiu A, Wang Y, Zhang G, Wang H
Polymers (Basel). 2022; 14(15).
PMID: 35956731
PMC: 9370904.
DOI: 10.3390/polym14153217.
A Comprehensive Review of the Evolution of Insulin Development and Its Delivery Method.
Sugumar V, Ang K, Alshanon A, Sethi G, Yong P, Looi C
Pharmaceutics. 2022; 14(7).
PMID: 35890301
PMC: 9320488.
DOI: 10.3390/pharmaceutics14071406.
Advances in oral peptide drug nanoparticles for diabetes mellitus treatment.
Li Y, Zhang W, Zhao R, Zhang X
Bioact Mater. 2022; 15:392-408.
PMID: 35386357
PMC: 8958389.
DOI: 10.1016/j.bioactmat.2022.02.025.
Versatile Oral Insulin Delivery Nanosystems: From Materials to Nanostructures.
Wang M, Wang C, Ren S, Pan J, Wang Y, Shen Y
Int J Mol Sci. 2022; 23(6).
PMID: 35328783
PMC: 8952690.
DOI: 10.3390/ijms23063362.
Emerging Theranostic Nanomaterials in Diabetes and Its Complications.
Liu Y, Zeng S, Ji W, Yao H, Lin L, Cui H
Adv Sci (Weinh). 2021; 9(3):e2102466.
PMID: 34825525
PMC: 8787437.
DOI: 10.1002/advs.202102466.
Potential Applications of Chitosan-Based Nanomaterials to Surpass the Gastrointestinal Physiological Obstacles and Enhance the Intestinal Drug Absorption.
Pathomthongtaweechai N, Muanprasat C
Pharmaceutics. 2021; 13(6).
PMID: 34203816
PMC: 8232820.
DOI: 10.3390/pharmaceutics13060887.
Transmucosal Solid Lipid Nanoparticles to Improve Genistein Absorption via Intestinal Lymphatic Transport.
Obinu A, Burrai G, Cavalli R, Galleri G, Migheli R, Antuofermo E
Pharmaceutics. 2021; 13(2).
PMID: 33669306
PMC: 7920073.
DOI: 10.3390/pharmaceutics13020267.
Smart Nanomaterials for Biomedical Applications-A Review.
Aflori M
Nanomaterials (Basel). 2021; 11(2).
PMID: 33557177
PMC: 7913901.
DOI: 10.3390/nano11020396.
Overcoming Multiple Absorption Barrier for Insulin Oral Delivery Using Multifunctional Nanoparticles Based on Chitosan Derivatives and Hyaluronic Acid.
Chen Z, Han S, Yang X, Xu L, Qi H, Hao G
Int J Nanomedicine. 2020; 15:4877-4898.
PMID: 32753869
PMC: 7358087.
DOI: 10.2147/IJN.S251627.
Oral delivery of insulin with intelligent glucose-responsive switch for blood glucose regulation.
Zhou X, Wu H, Long R, Wang S, Huang H, Xia Y
J Nanobiotechnology. 2020; 18(1):96.
PMID: 32664978
PMC: 7362448.
DOI: 10.1186/s12951-020-00652-z.
Dynamics and Rheological Behavior of Chitosan-Grafted-Polyacrylamide in Aqueous Solution upon Heating.
Wang M, Shangguan Y, Zheng Q
Polymers (Basel). 2020; 12(4).
PMID: 32326596
PMC: 7240601.
DOI: 10.3390/polym12040916.
How the Lack of Chitosan Characterization Precludes Implementation of the Safe-by-Design Concept.
Marques C, Som C, Schmutz M, Borges O, Borchard G
Front Bioeng Biotechnol. 2020; 8:165.
PMID: 32211394
PMC: 7077258.
DOI: 10.3389/fbioe.2020.00165.
Multifunctional oral delivery systems for enhanced bioavailability of therapeutic peptides/proteins.
Han Y, Gao Z, Chen L, Kang L, Huang W, Jin M
Acta Pharm Sin B. 2019; 9(5):902-922.
PMID: 31649842
PMC: 6804447.
DOI: 10.1016/j.apsb.2019.01.004.
Surface-modified mucoadhesive microparticles as a controlled release system for oral delivery of insulin.
Mumuni M, Kenechukwu F, Ernest O, Oluseun A, Abdulmumin B, Youngson D
Heliyon. 2019; 5(9):e02366.
PMID: 31535040
PMC: 6744591.
DOI: 10.1016/j.heliyon.2019.e02366.